Under the direction of co-founders Dr Lara Zibners and Thang Vo-Ta is reimagining vaginal drug delivery with its CallavidⓇ device—engineering a next-generation platform that improves both clinical outcomes and patient experience in women’s health. “Our revolutionary Callavid platform hugely increases the possibilities for intravaginal drug delivery by enabling treatments with enhanced efficacy, lower drug doses, …

Delighted to be named a 2025 finalist in the HLTH Europe Startup Pitch, sponsored by Haleon! Honoured to share the stage with some of the most innovative healthtech startups in Europe. See you in Amsterdam. 🇳🇱

We believe that true success in business must be measured not just by commercial milestones, but by the positive impact we create. To us, being a B Corp is more than a certification – it’s a daily commitment to balancing people, planet, profit, and purpose. B Lab’s rigorous standards provide a clear framework for accountability …

🎧 We loved this recent BBC Radio interview with Professor Siobhan Quenby MBE, who is leading the clinical trial of our progesterone-loaded Callavid at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. 🔗 Listen to the clip: https://lnkd.in/e9GkFDaD Professor Quenby shares how our pioneering drug delivery technology could support women globally experiencing threatened miscarriage — …

Grateful to BBC News for spotlighting our work on progesterone-Callavid®, our novel drug delivery technology aimed at helping treat threatened miscarriage. “The current delivery method can leak and cost the [British economy and] NHS up to £236m per year, health economists say. University Hospitals Coventry and Warwickshire (UHCW) NHS Trust is leading the trial and …

Trust leads clinical trial of pioneering product to tackle threatened miscarriage 8 April 2025 Experts from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are to lead a clinical trial of a novel device aimed at addressing threatened miscarriage. More than 150,000 women a year in the UK could be helped by Callavid® which is designed …

[From NIHR: National Institute for Health and Care Research] We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage. Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat …

Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials • Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials • Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each …

We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health. 💥 China Patent Grant for our Drug Delivery Device 🌏 At long last, one of our vaginal drug delivery applications in China has …

Our co-founders Lara and Thang have been named in the annual ‘200 Trailblazing Leaders in Women’s Health and FemTech’ for the second year running.  It’s a real who’s who of the influential leaders working to improve the access and quality of healthcare for women worldwide.  We’re delighted at the recognition for Lara & Thang and …